Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (2)
  • Open Access

    ARTICLE

    Combinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells

    BEHROOZ JOHARI1,2,#,*, MILAD PARVINZAD LEILAN1,#, MAHMOUD GHARBAVI3, YOUSEF MORTAZAVI1, ALI SHARAFI2, HAMED REZAEEJAM4

    Oncology Research, Vol.32, No.2, pp. 309-323, 2024, DOI:10.32604/or.2023.043576

    Abstract The Myc gene is the essential oncogene in triple-negative breast cancer (TNBC). This study investigates the synergistic effects of combining Myc decoy oligodeoxynucleotides-encapsulated niosomes-selenium hybrid nanocarriers with X-irradiation exposure on the MDA-MB-468 cell line. Decoy and scramble ODNs for Myc transcription factor were designed and synthesized based on promoter sequences of the Bcl2 gene. The nanocarriers were synthesized by loading Myc ODNs and selenium into chitosan (Chi-Se-DEC), which was then encapsulated in niosome-nanocarriers (NISM@Chi-Se-DEC). FT-IR, DLS, FESEM, and hemolysis tests were applied to confirm its characterization and physicochemical properties. Moreover, cellular uptake, cellular toxicity, apoptosis, cell cycle, and scratch repair… More > Graphic Abstract

    Combinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells

  • Open Access

    ARTICLE

    Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer

    Heming Lu*†1, Yuying Wu‡1, Xu Liu, Huixian Huang, Hailan Jiang, Chaohua Zhu, Yuping Man§, Zhaohong Chen, Xianfeng Long, Qiang Pang, Luxing Peng, Xianglong Li, Junzhao Gu, Shan Deng, Ligang Xing*

    Oncology Research, Vol.28, No.9, pp. 929-944, 2020, DOI:10.3727/096504021X16318716607908

    Abstract This phase II randomized clinical trial aimed to assess the efficacy and toxicity of Endostar, an antiangiogenesis inhibitor, combined with concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC). Patients with LACC were randomly assigned to either CCRT plus Endostar (CCRT+E arm) or CCRT alone (CCRT arm). All patients received pelvic intensity-modulated radiation therapy (IMRT) and brachytherapy. Weekly cisplatin was administered concurrently with IMRT. Patients in the CCRT+E arm also received concurrent Endostar every 3 weeks for two cycles. The primary endpoint was progression-free survival (PFS) and acute toxicities. The exploratory endpoint was the impact of vascular endothelial growth factor… More >

Displaying 1-10 on page 1 of 2. Per Page